Bengaluru: Medical equipment maker Thermo Fisher Scientific said on Monday it would sell its microbiology business to private equity firm Astorg for about $1.08 billion.
Deal consists of cash and a $50 million seller note.
The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical and food safety applications.
The unit, a part of Thermo Fisher’s specialty diagnostics segment, recorded $645 million in revenue in 2025.
The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value,” said Marc Casper, chief executive officer of Thermo Fisher.
The company expects the transaction to close in the second half of 2026.
Thermo Fisher expects the deal to be dilutive to adjusted earnings per share by $0.15 in the first full year after it closes.
The company said it would provide details on the expected impact to its 2026 forecast during its second quarter earnings call.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
